Unmet needs in the management of immune‐mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK—A modified‐Delphi study

Abstract Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is an ultra‐rare, blood‐clotting disorder. Management historically relies on plasma exchange and immunosuppression; however, a 10%–20% mortality rate is still observed. Caplacizumab binds to von Willebrand factor and directly inhibi...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:eJHaem
المؤلفون الرئيسيون: Marie Scully, Tina Dutt, Will Lester, Emily Farrington, Stevie Lockwood, Richard Perry, Steve Holmes
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Wiley 2022-08-01
الموضوعات:
ADAMTS13
caplacizumab
management
thrombocytopenic purpura
unmet need
الوصول للمادة أونلاين:https://doi.org/10.1002/jha2.435

الانترنت

https://doi.org/10.1002/jha2.435

مواد مشابهة